Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX: PBT) covers the month of November 2014. The document reports the results of the Annual General Meeting (AGM) held on November 13, 2014. Note: The metadata provided lists "Alterity Therapeutics Ltd," but the filing text explicitly identifies the registrant as Prana Biotechnology Limited.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a corporate governance disclosure regarding AGM voting results and contains no financial statements or operational metrics.
Material Changes and Voting Results
All resolutions presented at the AGM were carried on a show of hands. Detailed proxy voting results are as follows:
- Adoption of Remuneration Report: Passed with 91.47% of valid proxies in favor (48,789,215 votes for).
- Election of Director - Professor Ira Shoulson: Passed with 97.89% support (54,808,276 votes for).
- Re-election of Director - Mr Peter Marks: Passed with 93.52% support (51,212,435 votes for).
- Re-election of Director - Mr Lawrence Gozlan: Passed with 93.42% support (51,144,355 votes for).
- Ratification of ATM Securities: Passed with 93.42% support (51,144,355 votes for).
The Chairman exercised undirected proxies in favor of all resolutions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the announcement of AGM outcomes.
Key Facts for Investor Verification
- Confirm the registrant name is Prana Biotechnology Limited, not Alterity Therapeutics Ltd.
- Verify the successful ratification of the At-The-Market (ATM) securities issuance program.
- Note the high level of shareholder support for the re-election of the current board directors.
- Check subsequent filings for financial data, as this 6-K contains no financial performance metrics.